Isolinderalactone Resistance to the Liver Injury Induced by Oxaliplatin in Rats Through Inhibiting IL-6/STAT3 Signal Pathway


Cite item

Full Text

Abstract

Background: Oxaliplatin (OXA) is easy to cause sinusoidal obstruction syndrome (SOS), leading to liver injury. Isolinderalactone (ILL), one of the main components of Lindera aggregate, has been reported to have a protecting effect on the liver. However, it is unclear whether ILL has a therapeutic effect on liver injury caused by OXA. This study aims to determine the effect of ILL on the prevention and treatment of OXA-induced liver injury and to provide a basis for the chemotherapy of gastrointestinal tumors.

Methods: Intraperitoneal injection of folinic acid, 5-fluorouracil, and OXA was administered on the SOS rat model for 7 weeks. The indexes of liver function were measured by biochemical kit. The ratio of liver weight to body weight was calculated. The pathological analysis of the liver was scored with the SOS scoring standard, fibrosis was evaluated with a four-point scale. The expression of inflammation factors was detected by Real-Time PCR, and the related indexes of IL-6/STAT3 were examined by Western blot analysis.

Results: ILL down-regulated the portal vein pressure and alleviated the abnormal liver function of SOS rats and improved the liver lesions. ILL inhibited the SOS by inhibiting IL-6/STAT3.

Conclusion: ILL resistance to liver injury through inhibiting IL-6/STAT3 signal pathway.

About the authors

Rongwei Lin

Department of General Surgery, Traditional Chinese Medical Hospital of Tiantai County

Email: info@benthamscience.net

Yang Zhou

School of Medical Sciences, Wenzhou Medical University

Email: info@benthamscience.net

Chao Hu

Department of Hepatobiliary and Pancreatic Surgery,, Zhejiang Cancer Hospital

Email: info@benthamscience.net

Hongqing Yao

Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Cancer Hospital

Email: info@benthamscience.net

Wangxun Jin

School of Medical Sciences, Wenzhou Medical University, Wenzhou

Author for correspondence.
Email: info@benthamscience.net

References

  1. Fritsch, R.; Hoeppner, J. Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma. Expert Rev. Gastroenterol. Hepatol., 2019, 13(4), 285-291. doi: 10.1080/17474124.2019.1573143 PMID: 30791774
  2. Li, Y.; Sun, Z.; Cui, Y.; Zhang, H.; Zhang, S.; Wang, X.; Liu, S.; Gao, Q. Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer. Bioorg. Chem., 2021, 107, 104636. doi: 10.1016/j.bioorg.2021.104636 PMID: 33465670
  3. Zhu, C.; Ren, X.; Liu, D.; Zhang, C. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology, 2021, 460, 152882. doi: 10.1016/j.tox.2021.152882 PMID: 34352347
  4. Liu, L.; Zhang, W.; Zhuge, Y.Z. Review on diagnostic criteria of hepatic sinusoidal obstruction syndrome. Zhonghua Gan Zang Bing Za Zhi, 2020, 28(12), 1064-1068. PMID: 34865358
  5. Miyamoto, T.; Domoto, R.; Sekiguchi, F.; Kamaguchi, R.; Nishimura, R.; Matsuno, M.; Tsubota, M.; Fujitani, M.; Hatanaka, S.; Koizumi, Y.; Wang, D.; Nishibori, M.; Kawabata, A. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. J. Pharmacol. Sci., 2022, 148(3), 315-325. doi: 10.1016/j.jphs.2022.01.006 PMID: 35177211
  6. Kuo, P.C.; Wu, Y.H.; Hung, H.Y.; Lam, S.H.; Ma, G.H.; Kuo, L.M.; Hwang, T.L.; Kuo, D.H.; Wu, T.S. Anti-inflammatory principles from Lindera aggregata. Bioorg. Med. Chem. Lett., 2020, 30(13), 127224. doi: 10.1016/j.bmcl.2020.127224 PMID: 32359855
  7. Yang, J.J.; Chen, Y.; Guo, M.L.; Chou, G.X. Chemical constituents from the roots of Lindera aggregata and their biological activities. J. Nat. Med., 2020, 74(2), 441-447. doi: 10.1007/s11418-019-01385-6 PMID: 31912311
  8. Chen, Y.; Li, R.; Hu, N.; Yu, C.; Song, H.; Li, Y.; Dai, Y.; Guo, Z.; Li, M.; Zheng, Y.; Guo, Z.; Qi, Y. Baihe Wuyao decoction ameliorates CCl4-induced chronic liver injury and liver fibrosis in mice through blocking TGF-β1/Smad2/3 signaling, anti-inflammation and anti-oxidation effects. J. Ethnopharmacol., 2020, 263, 113227. doi: 10.1016/j.jep.2020.113227 PMID: 32783983
  9. Wang, J.W.; Chen, X.Y.; Hu, P.Y.; Tan, M.M.; Tang, X.G.; Huang, M.C.; Lou, Z.H. Effects of Linderae radix extracts on a rat model of alcoholic liver injury. Exp. Ther. Med., 2016, 11(6), 2185-2192. doi: 10.3892/etm.2016.3244 PMID: 27313665
  10. Yen, M.C.; Shih, Y.C.; Hsu, Y.L.; Lin, E.S.; Lin, Y.S.; Tsai, E.M.; Ho, Y.A.W.E.N.; Hou, M.F.; Kuo, P.O.L.I.N. Isolinderalactone enhances the inhibition of SOCS3 on STAT3 activity by decreasing miR-30c in breast cancer. Oncol. Rep., 2016, 35(3), 1356-1364. doi: 10.3892/or.2015.4503 PMID: 26707189
  11. Kwak, A.W.; Park, J.W.; Lee, S.O.; Lee, J.Y.; Seo, J.; Yoon, G.; Lee, M.H.; Choi, J.S.; Shim, J.H. Isolinderalactone sensitizes oxaliplatin-resistance colorectal cancer cells through JNK/p38 MAPK signaling pathways. Phytomedicine, 2022, 105, 154383. doi: 10.1016/j.phymed.2022.154383 PMID: 35987016
  12. Rajina, S.; Kim, W.J.; Shim, J.H.; Chun, K.S.; Joo, S.H.; Shin, H.K.; Lee, S.Y.; Choi, J.S. Isolinderalactone induces cell death via mitochondrial superoxide- and STAT3-mediated pathways in human ovarian cancer cells. Int. J. Mol. Sci., 2020, 21(20), 7530. doi: 10.3390/ijms21207530 PMID: 33066004
  13. Robinson, S.M.; Mann, J.; Vasilaki, A.; Mathers, J.; Burt, A.D.; Oakley, F.; White, S.A.; Mann, D.A. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J. Hepatol., 2013, 59(2), 318-326. doi: 10.1016/j.jhep.2013.04.014 PMID: 23624001
  14. Zhao, J.; Liu, X.; Chen, Y.; Zhang, L.S.; Zhang, Y.R.; Ji, D.R.; Liu, S.M.; Jia, M.Z.; Zhu, Y.H.; Qi, Y.F.; Lu, F.M.; Yu, Y.R. STAT3 promotes schistosome-induced liver injury by inflammation, oxidative stress, proliferation, and apoptosis signal pathway. Infect. Immun., 2021, 89(3), e00309-20. doi: 10.1128/IAI.00309-20 PMID: 33257536
  15. Park, S.H.; Lee, S.S.; Sung, J.Y.; Na, K.; Kim, H.J.; Kim, S.Y.; Park, B.J.; Byun, J.H. Noninvasive assessment of hepatic sinusoidal obstructive syndrome using acoustic radiation force impulse elastography imaging: A proof-of-concept study in rat models. Eur. Radiol., 2018, 28(5), 2096-2106. doi: 10.1007/s00330-017-5179-z PMID: 29218616
  16. Corbacioglu, S.; Jabbour, E.J.; Mohty, M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol. Blood Marrow Transplant., 2019, 25(7), 1271-1280. doi: 10.1016/j.bbmt.2019.02.018 PMID: 30797942
  17. Slade, J.H.; Alattar, M.L.; Fogelman, D.R.; Overman, M.J.; Agarwal, A.; Maru, D.M.; Coulson, R.L.; Charnsangavej, C.; Vauthey, J.N.; Wolff, R.A.; Kopetz, S. Portal hypertension associated with oxaliplatin administration: Clinical manifestations of hepatic sinusoidal injury. Clin. Colorectal Cancer, 2009, 8(4), 225-230. doi: 10.3816/CCC.2009.n.038 PMID: 19822514
  18. Overman, M.J.; Maru, D.M.; Charnsangavej, C.; Loyer, E.M.; Wang, H.; Pathak, P.; Eng, C.; Hoff, P.M.; Vauthey, J.N.; Wolff, R.A.; Kopetz, S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J. Clin. Oncol., 2010, 28(15), 2549-2555. doi: 10.1200/JCO.2009.27.5701 PMID: 20406923
  19. Lu, Y.; Lin, Y.; Huang, X.; Wu, S.; Wei, J.; Yang, C. Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non alcoholic fatty liver disease mouse model. Int. J. Mol. Med., 2019, 43(6), 2398-2408. doi: 10.3892/ijmm.2019.4154 PMID: 30942432
  20. Ribero, D.; Wang, H.; Donadon, M.; Zorzi, D.; Thomas, M.B.; Eng, C.; Chang, D.Z.; Curley, S.A.; Abdalla, E.K.; Ellis, L.M.; Vauthey, J.N. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer, 2007, 110(12), 2761-2767. doi: 10.1002/cncr.23099 PMID: 17960603
  21. Overman, M.J.; Ferrarotto, R.; Raghav, K.; George, B.; Qiao, W.; Machado, K.K.; Saltz, L.B.; Mazard, T.; Vauthey, J.N.; Hoff, P.M.; Hobbs, B.; Loyer, E.M.; Kopetz, S. The addition of bevacizumab to oxaliplatin-based chemotherapy: Impact upon hepatic sinusoidal injury and thrombocytopenia. J. Natl. Cancer Inst., 2018, 110(8), 888-894. doi: 10.1093/jnci/djx288 PMID: 29346573
  22. Zou, X.; Wang, Y.; Peng, C.; Wang, B.; Niu, Z.; Li, Z.; Niu, J. Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin induced model of liver injury. Int. J. Mol. Med., 2018, 42(4), 2020-2030. doi: 10.3892/ijmm.2018.3787 PMID: 30066834
  23. Lu, Y.; Wu, S.; Xiang, B.; Li, L.; Lin, Y. Curcumin attenuates oxaliplatin-induced liver injury and oxidative stress by activating the Nrf2 pathway. Drug Des. Devel. Ther., 2020, 14, 73-85. doi: 10.2147/DDDT.S224318 PMID: 32021093
  24. Gan, L.S.; Zheng, Y.L.; Mo, J.X.; Liu, X.; Li, X.H.; Zhou, C.X. Sesquiterpene lactones from the root tubers of Lindera aggregata. J. Nat. Prod., 2009, 72(8), 1497-1501. doi: 10.1021/np900354q PMID: 19639966
  25. Chang, W.; Lin, E.S.; Tsai, M.J.; Huang, M.S.; Kuo, P.L. Isolinderalactone inhibits proliferation of A549 human non-small cell lung cancer cells by arresting the cell cycle at the G0/G1 phase and inducing a Fas receptor and soluble Fas ligand-mediated apoptotic pathway. Mol. Med. Rep., 2014, 9(5), 1653-1659. doi: 10.3892/mmr.2014.2015 PMID: 24604009
  26. Deng, Y.; Li, Y. Linderalactone inhibits human lung cancer growth by modulating the expression of apoptosis-related proteins, G2/M cell cycle arrest and inhibition of JAK/STAT signalling pathway. J. BUON, 2019, 24(2), 566-571. PMID: 31128007
  27. Chuang, C.H.; Wang, L.Y.; Wong, Y.; Lin, E.S. Anti-metastatic effects of isolinderalactone via the inhibition of MMP-2 and up regulation of NM23-H1 expression in human lung cancer A549 cells. Oncol. Lett., 2018, 15(4), 4690-4696. doi: 10.3892/ol.2018.7862 PMID: 29541242
  28. Hwang, J.Y.; Park, J.H.; Kim, M.J.; Kim, W.J.; Ha, K.T.; Choi, B.T.; Lee, S.Y.; Shin, H.K. Isolinderalactone regulates the BCL-2/caspase-3/PARP pathway and suppresses tumor growth in a human glioblastoma multiforme xenograft mouse model. Cancer Lett., 2019, 443, 25-33. doi: 10.1016/j.canlet.2018.11.027 PMID: 30503550
  29. Park, J.H.; Kim, M.J.; Kim, W.J.; Kwon, K.D.; Ha, K.T.; Choi, B.T.; Lee, S.Y.; Shin, H.K. Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models. Cancer Lett., 2020, 478, 71-81. doi: 10.1016/j.canlet.2020.03.009 PMID: 32173479
  30. Santoro, V.; Jia, R.; Thompson, H.; Nijhuis, A.; Jeffery, R.; Kiakos, K.; Silver, A.R.; Hartley, J.A.; Hochhauser, D. Role of reactive oxygen species in the abrogation of oxaliplatin activity by cetuximab in colorectal cancer. J. Natl. Cancer Inst., 2015, 108(6), djv394. doi: 10.1093/jnci/djv394 PMID: 26719345
  31. Tajima, H.; Ohta, T.; Miyashita, T.; Nakanuma, S.; Matoba, M.; Miyata, T.; Sakai, S.; Okamoto, K.; Makino, I.; Kinoshita, J.; Hayashi, H.; Nakamura, K.; Oyama, K.; Inokuchi, M.; Nakagawara, H.; Takamura, H.; Kitagawa, H.; Fushida, S.; Ikeda, H. Oxaliplatin-based chemotherapy induces extravasated platelet aggregation in the liver. Mol. Clin. Oncol., 2015, 3(3), 555-558. doi: 10.3892/mco.2015.512 PMID: 26137266
  32. Rubbia-Brandt, L.; Audard, V.; Sartoretti, P.; Roth, A.D.; Brezault, C.; Le Charpentier, M.; Dousset, B.; Morel, P.; Soubrane, O.; Chaussade, S.; Mentha, G.; Terris, B. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann. Oncol., 2004, 15(3), 460-466. doi: 10.1093/annonc/mdh095 PMID: 14998849

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bentham Science Publishers